JP2017501978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501978A5 JP2017501978A5 JP2016533153A JP2016533153A JP2017501978A5 JP 2017501978 A5 JP2017501978 A5 JP 2017501978A5 JP 2016533153 A JP2016533153 A JP 2016533153A JP 2016533153 A JP2016533153 A JP 2016533153A JP 2017501978 A5 JP2017501978 A5 JP 2017501978A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- alkyl
- optionally substituted
- methyl
- oxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 72
- -1 alkyl carboxylic acid Chemical class 0.000 claims 64
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 150000002576 ketones Chemical class 0.000 claims 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 150000003462 sulfoxides Chemical class 0.000 claims 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 229940124530 sulfonamide Drugs 0.000 claims 3
- 150000003456 sulfonamides Chemical class 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- RLVLKCZGAIDTIH-INIZCTEOSA-N 2-[[(2S)-2-[(4-bromophenyl)carbamoyloxy]-3-phenylpropanoyl]-methylamino]acetic acid Chemical compound BrC1=CC=C(C=C1)NC(=O)O[C@H](C(=O)N(C)CC(=O)O)CC1=CC=CC=C1 RLVLKCZGAIDTIH-INIZCTEOSA-N 0.000 claims 2
- VBHOXQBCWWGYMA-HNNXBMFYSA-N 2-[[(2S)-2-[(4-bromophenyl)carbamoyloxy]-3-phenylpropanoyl]amino]acetic acid Chemical compound BrC1=CC=C(C=C1)NC(=O)O[C@H](C(=O)NCC(=O)O)CC1=CC=CC=C1 VBHOXQBCWWGYMA-HNNXBMFYSA-N 0.000 claims 2
- RXDDSMKTPNDCPY-ZDUSSCGKSA-N 2-[[(2S)-2-[(4-bromophenyl)carbamoyloxy]-4-methylpentanoyl]-methylamino]acetic acid Chemical compound BrC1=CC=C(C=C1)NC(=O)O[C@H](C(=O)N(C)CC(=O)O)CC(C)C RXDDSMKTPNDCPY-ZDUSSCGKSA-N 0.000 claims 2
- GOBOZYKLKKNCLD-HNNXBMFYSA-N 2-[[(2S)-2-[(4-bromophenyl)carbamoyloxy]-4-methylpentanoyl]-propan-2-ylamino]acetic acid Chemical compound BrC1=CC=C(C=C1)NC(=O)O[C@H](C(=O)N(C(C)C)CC(=O)O)CC(C)C GOBOZYKLKKNCLD-HNNXBMFYSA-N 0.000 claims 2
- ZUGXPLUCHILJHR-HNNXBMFYSA-N 2-[[(2S)-2-[(4-bromophenyl)carbamoyloxy]-4-methylpentanoyl]-propylamino]acetic acid Chemical compound BrC1=CC=C(C=C1)NC(=O)O[C@H](C(=O)N(CCC)CC(=O)O)CC(C)C ZUGXPLUCHILJHR-HNNXBMFYSA-N 0.000 claims 2
- SSNZCRIXFRGNBP-LBPRGKRZSA-N 2-[[(2S)-2-[(4-bromophenyl)carbamoyloxy]-4-methylpentanoyl]amino]acetic acid Chemical compound BrC1=CC=C(C=C1)NC(=O)O[C@H](C(=O)NCC(=O)O)CC(C)C SSNZCRIXFRGNBP-LBPRGKRZSA-N 0.000 claims 2
- BIWHNGFKVXRCJU-HNNXBMFYSA-N 2-[[(2S)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoyloxy]pentanoyl]-propan-2-ylamino]acetic acid Chemical compound C(C)(C)N(C([C@H](CC(C)C)OC(=O)NC1=CC=C(C=C1)C(F)(F)F)=O)CC(=O)O BIWHNGFKVXRCJU-HNNXBMFYSA-N 0.000 claims 2
- GYBQQXUCXPLSHJ-LBPRGKRZSA-N 2-[[(2S)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoyloxy]pentanoyl]amino]acetic acid Chemical compound CC(C[C@@H](C(=O)NCC(=O)O)OC(NC1=CC=C(C=C1)C(F)(F)F)=O)C GYBQQXUCXPLSHJ-LBPRGKRZSA-N 0.000 claims 2
- WFQZQXWDIHFZCV-AWEZNQCLSA-N 2-[[(2s)-2-[(4-bromophenyl)carbamoyloxy]-4-methylpentanoyl]-ethylamino]acetic acid Chemical compound OC(=O)CN(CC)C(=O)[C@H](CC(C)C)OC(=O)NC1=CC=C(Br)C=C1 WFQZQXWDIHFZCV-AWEZNQCLSA-N 0.000 claims 2
- FXYKAQXKKAUDMM-AWEZNQCLSA-N 2-[ethyl-[(2S)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoyloxy]pentanoyl]amino]acetic acid Chemical compound C(C)N(C([C@H](CC(C)C)OC(NC1=CC=C(C=C1)C(F)(F)F)=O)=O)CC(=O)O FXYKAQXKKAUDMM-AWEZNQCLSA-N 0.000 claims 2
- WHXLRYXVUALUQB-ZDUSSCGKSA-N 2-[methyl-[(2S)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoyloxy]pentanoyl]amino]acetic acid Chemical compound CN(C([C@H](CC(C)C)OC(NC1=CC=C(C=C1)C(F)(F)F)=O)=O)CC(=O)O WHXLRYXVUALUQB-ZDUSSCGKSA-N 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000037390 scarring Effects 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- CSUYMIRJKBHKBL-AWEZNQCLSA-N (2S)-2-[(4-bromophenyl)carbamoyloxy]-3-phenylpropanoic acid Chemical compound BrC1=CC=C(C=C1)NC(=O)O[C@H](C(=O)O)CC1=CC=CC=C1 CSUYMIRJKBHKBL-AWEZNQCLSA-N 0.000 claims 1
- RTLGSMNHKVJCTI-NSHDSACASA-N (2S)-2-[(4-bromophenyl)carbamoyloxy]-4-methylpentanoic acid Chemical compound BrC1=CC=C(C=C1)NC(=O)O[C@H](C(=O)O)CC(C)C RTLGSMNHKVJCTI-NSHDSACASA-N 0.000 claims 1
- GNUVETDOQIYMPS-NSHDSACASA-N (2S)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoyloxy]pentanoic acid Chemical compound CC(C[C@@H](C(=O)O)OC(NC1=CC=C(C=C1)C(F)(F)F)=O)C GNUVETDOQIYMPS-NSHDSACASA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 208000012641 Pigmentation disease Diseases 0.000 claims 1
- 206010036346 Posterior capsule opacification Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- ZIHQUWYJSTVYAT-UHFFFAOYSA-N [NH-][N+]([O-])=O Chemical class [NH-][N+]([O-])=O ZIHQUWYJSTVYAT-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000000069 hyperpigmentation Diseases 0.000 claims 1
- 230000003810 hyperpigmentation Effects 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 230000035168 lymphangiogenesis Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 235000011007 phosphoric acid Nutrition 0.000 claims 1
- 150000003016 phosphoric acids Chemical class 0.000 claims 1
- 230000008832 photodamage Effects 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- ZJMMUGXBVCRXCD-KRWDZBQOSA-N tert-butyl (2S)-2-[(4-bromophenyl)carbamoyloxy]-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)[C@H](CC1=CC=CC=C1)OC(=O)NC1=CC=C(Br)C=C1 ZJMMUGXBVCRXCD-KRWDZBQOSA-N 0.000 claims 1
- LXMIBWJZEQKHCO-AWEZNQCLSA-N tert-butyl (2S)-2-[(4-bromophenyl)carbamoyloxy]-4-methylpentanoate Chemical compound BrC1=CC=C(C=C1)NC(=O)O[C@H](C(=O)OC(C)(C)C)CC(C)C LXMIBWJZEQKHCO-AWEZNQCLSA-N 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
- 0 CC(*)(C(N(*)C(*)(*)*)=O)OC(Nc1c(*)c(*)c(*)c(*)c1*)=O Chemical compound CC(*)(C(N(*)C(*)(*)*)=O)OC(Nc1c(*)c(*)c(*)c(*)c1*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907320P | 2013-11-21 | 2013-11-21 | |
| US61/907,320 | 2013-11-21 | ||
| PCT/US2014/066608 WO2015077451A1 (en) | 2013-11-21 | 2014-11-20 | Phenylcarbamate derivatives as formyl peptide receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501978A JP2017501978A (ja) | 2017-01-19 |
| JP2017501978A5 true JP2017501978A5 (enExample) | 2017-11-24 |
| JP6496728B2 JP6496728B2 (ja) | 2019-04-03 |
Family
ID=52101595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533153A Active JP6496728B2 (ja) | 2013-11-21 | 2014-11-20 | ホルミルペプチド受容体の調節因子としてのカルバミン酸フェニル誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9926264B2 (enExample) |
| EP (1) | EP3071548B1 (enExample) |
| JP (1) | JP6496728B2 (enExample) |
| KR (1) | KR102310615B1 (enExample) |
| CN (1) | CN105705484B (enExample) |
| AU (1) | AU2014352922B2 (enExample) |
| BR (1) | BR112016011417A8 (enExample) |
| CA (1) | CA2930084A1 (enExample) |
| RU (1) | RU2703725C1 (enExample) |
| WO (1) | WO2015077451A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012329098B2 (en) | 2011-10-26 | 2017-08-03 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| JP6196328B2 (ja) | 2013-03-06 | 2017-09-13 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| ES2788700T3 (es) | 2014-05-21 | 2020-10-22 | Allergan Inc | Derivados de imidazol como moduladores del receptor de péptido formilado |
| GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05163221A (ja) * | 1991-12-17 | 1993-06-29 | Fujirebio Inc | オキシ酸誘導体 |
| CA2383002A1 (en) | 1999-08-27 | 2001-03-08 | Cytovia, Inc. | Substituted .alpha.-hydroxy acid caspase inhibitors and the use thereof |
| CN100506802C (zh) * | 2004-06-04 | 2009-07-01 | 中国科学院上海药物研究所 | 一类甲酰肽样受体-1调节剂、其制备方法和用途 |
| CN102414168B (zh) * | 2009-05-18 | 2014-05-21 | 埃科特莱茵药品有限公司 | 用作为alx受体和/或fprl2激动剂的桥联螺[2.4]庚烷衍生物 |
| AU2011336973A1 (en) | 2010-12-03 | 2013-07-11 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity |
| AU2012214265A1 (en) | 2011-02-11 | 2013-09-05 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| AU2012329098B2 (en) | 2011-10-26 | 2017-08-03 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8492556B2 (en) | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8541577B2 (en) | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| AU2013221749A1 (en) | 2012-02-16 | 2014-09-11 | Allergan, Inc. | Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators |
| SG11201406629VA (en) | 2012-04-16 | 2014-11-27 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| US9428549B2 (en) | 2013-07-16 | 2016-08-30 | Allegran, Inc. | Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators |
| WO2015116574A1 (en) | 2014-01-29 | 2015-08-06 | Allergan, Inc. | Urea hydantoin derivatives as formyl peptide modulators |
| US9920013B2 (en) | 2014-01-29 | 2018-03-20 | Allergan, Inc. | 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| ES2788700T3 (es) | 2014-05-21 | 2020-10-22 | Allergan Inc | Derivados de imidazol como moduladores del receptor de péptido formilado |
-
2014
- 2014-11-20 JP JP2016533153A patent/JP6496728B2/ja active Active
- 2014-11-20 CA CA2930084A patent/CA2930084A1/en not_active Abandoned
- 2014-11-20 US US15/034,793 patent/US9926264B2/en active Active
- 2014-11-20 CN CN201480061275.4A patent/CN105705484B/zh not_active Expired - Fee Related
- 2014-11-20 BR BR112016011417A patent/BR112016011417A8/pt not_active Application Discontinuation
- 2014-11-20 RU RU2016119347A patent/RU2703725C1/ru active
- 2014-11-20 AU AU2014352922A patent/AU2014352922B2/en not_active Ceased
- 2014-11-20 KR KR1020167016187A patent/KR102310615B1/ko not_active Expired - Fee Related
- 2014-11-20 WO PCT/US2014/066608 patent/WO2015077451A1/en not_active Ceased
- 2014-11-20 EP EP14812353.2A patent/EP3071548B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501978A5 (enExample) | ||
| RU2017129434A (ru) | Амидные производные n-карбамид-замещенных аминокислот как модуляторы формилпептидного рецептора-1 (fprl-1) | |
| JP2016529235A5 (enExample) | ||
| JP2015520130A5 (enExample) | ||
| IL263314A (en) | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | |
| RU2016119347A (ru) | Производные фенилкарбамата в качестве модуляторов формилпептидного рецептора | |
| ES2232114T3 (es) | Derivados de cicloalqueno, procedimiento para su produccion, y uso. | |
| NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| JP2014525426A5 (enExample) | ||
| RU2013132650A (ru) | Серные производные в качестве модуляторов хемокиновых рецепторов | |
| JP2014525427A5 (enExample) | ||
| JP2019505541A5 (enExample) | ||
| RU2013150332A (ru) | Замещенные бициклические метиламинные производные как модуляторы рецепторов сфингозин-1-фосфата | |
| NZ603198A (en) | Novel hydroxamic acid derivative | |
| JP2009542815A5 (enExample) | ||
| RU2016104844A (ru) | Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора | |
| JP2014502979A5 (enExample) | ||
| JP2016512193A5 (enExample) | ||
| EA201591775A1 (ru) | Замещенные ароматические соединения и связанный с ними способ лечения фиброза | |
| RU2009136911A (ru) | Соединения, представляющие собой стиролильные производные, для лечения офтальмических заболеваний и расстройств | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| JP2012526082A5 (enExample) | ||
| JP2017520528A5 (enExample) | ||
| WO2013057251A3 (en) | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| JP2017537937A5 (enExample) |